Structure‐Based Design, Synthesis, and Biological Evaluation of Triazole‐Based smHDAC8 Inhibitors. (9th January 2020)

• Record Type: Journal Article
• Authors: Kalinin, Dmitrii V.; Jana, Sunit K.; Pfafenrot, Maxim; Chakrabarti, Alokta; Melesina, Jelena; Shaik, Tajith B.; Lancelot, Julien; Pierce, Raymond J.; Sippl, Wolfgang; Romier, Christophe; Jung, Manfred; Holl, Ralph
• Is Part Of: ChemMedChem. Volume 15:Number 7(2020)
• Page Start: 571
• Page End: 584
• Publication Date: 2020-01-09
• Subjects: Schistosoma mansoni -- histone deacetylases -- triazole derivatives -- crystal structures -- molecular docking studies; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1002/cmdc.201900583
• Languages: English
• ISSNs: 1860-7179

Abstract

Abstract: Schistosomiasis is a neglected tropical disease caused by parasitic flatworms of the genus Schistosoma, which affects over 200 million people worldwide and leads to at least 300, 000 deaths every year. In this study, initial screening revealed the triazole‐based hydroxamate 2 b ( N ‐hydroxy‐1‐phenyl‐1 H ‐1, 2, 3‐triazole‐4‐carboxamide) exhibiting potent inhibitory activity toward the novel antiparasitic target Schistosoma mansoni histone deacetylase 8 (smHDAC8) and promising selectivity over the major human HDACs. Subsequent crystallographic studies of the 2 b /smHDAC8 complex revealed key interactions between the inhibitor and the enzyme's active site, thus explaining the unique selectivity profile of the inhibitor. Further chemical modifications of 2 b led to the discovery of 4‐fluorophenoxy derivative 21 (1‐[5‐chloro‐2‐(4‐fluorophenoxy)phenyl]‐ N ‐hydroxy‐1 H ‐1, 2, 3‐triazole‐4‐carboxamide), a nanomolar smHDAC8 inhibitor (IC50 =0.5 μM), exceeding the smHDAC8 inhibitory activity of 2 b and SAHA (vorinostat), while exhibiting an improved selectivity profile over the investigated human HDACs. Collectively, this study reveals specific interactions between smHDAC8 and the synthesized triazole‐based inhibitors and demonstrates that these small molecules represent promising lead structures, which could be further developed in the search for novel drugs for the treatment of schistosomiasis. Abstract : Triazole‐based smHDAC8 inhibitors exhibiting an improved selectivity profile over human HDACs were synthesized, evaluated in in vitro inhibition assays, and tested for their effects on the viability of Schistosoma mansoni larvae. Crystallographic as well as molecular docking studies revealed key interactions between smHDAC8 and the developed triazole derivatives, thus explaining their unique selectivity profile.